Hematologic Oncology

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.

Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.

The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.

Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory follicular lymphoma.

Courtney DiNardo, MD, MSCE, discusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Richard R. Furman, MD, discusses the findings from the analysis and highlights the differences between first- and second-generation BTK inhibitors in CLL.

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).

Courtney DiNardo, MD, MSCE, discusses the results of the analysis evaluating the timing of response to venetoclax-based combinations, and related disease features, in older patients with AML.

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.

Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis and is characterized by rapidly progressive organ failure and eventually patient demise, if not promptly recognized and treated.

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).